23-08-2002 дата публикации
Номер: PE20020664A1
SE REFIERE A ESTERES OXIGENADOS DE ACIDOS 4-YODO FENILAMINO BENZHIDROXAMICOS DE FORMULA I DONDE R1 ES H, HALOGENO, NITRO; R2 Y R3 SON H, F; R4 ES H, Br, I, Cl, F; R5 ES H, HALOGENO, OH, ALQUILO C1-C8, ALCOXI C1-C8, TRIFLUOROMETILO, CIANO; n ES 1-5; R6, R7, R8, R9 Y R10 SON H, ALQUILO C1-C8, CICLOALQUILO C3-C8, HIDROXI, ALCOXI C1-C8, ENTRE OTROS; W ES O, NRa; R11 ES H, ALQUILO C1-C8, ALQUENILO C2-C6, CICLOALQUILO C3-C8, ENTRE OTROS. ADEMAS SE REFIERE AL USO EN COMBINACION CON UN AGENTE QUIMIOTERAPICO COMO PACLITAXEL, DOCETAXEL, VINCRISTINA, VINBLASTINA, VINORELBINA, VINFLUNINA; TAMBIEN SE REFIERE A LAS FORMAS CRISTALINAS I Y II DE N-(2,3-DIHIDROXI-PROPOXI)-3,4-DIFLUORO-2-(2-FLUORO-4-YODO-FENILAMINO)-BENZAMIDA QUE SE CARATERIZA POR SU PATRON DE DIFRACCION DE RAYOS X. SON COMPUESTOS PREFERIDOS 3,4 DIFLUORO-2-(2-FLUORO-4-YODO-FENILAMINO)-N-(2-HIDROXI-ETOXI)-BENZAMIDA, 5-CLORO-2-(2-CLORO-4-YODO-FENILAMINO)-N-(2,3-DIHIDROXI-PROPOXI)-3,4-DIFLUORO-BENZAMIDA, ENTRE OTROS. LOS COMPUESTOS INHIBEN A LAS ENZIMAS QUINASAS MAPK/ERK (MEK) Y PUEDEN SER UTILES PARA EL TRATAMIENTO DEL CANCER, RESTENOSIS, PSORIASIS, ATEROSCLEROSIS REFERS TO OXYGEN ESTERS OF 4-IODINE PHENYLAMINE BENZHYDROXAMIC ACIDS OF FORMULA I WHERE R1 IS H, HALOGEN, NITRO; R2 AND R3 ARE H, F; R4 IS H, Br, I, Cl, F; R5 IS H, HALOGEN, OH, C1-C8 ALKYL, C1-C8 ALCOXY, TRIFLUOROMETHYL, CYANE; n IS 1-5; R6, R7, R8, R9 AND R10 ARE H, C1-C8 ALKYL, C3-C8 CYCLOALKYL, HYDROXY, C1-C8 ALCOXY, AMONG OTHERS; W ES O, NRa; R11 IS H, C1-C8 ALKYL, C2-C6 ALKENYL, C3-C8 CYCLOALKYL, AMONG OTHERS. ALSO REFERS TO THE USE IN COMBINATION WITH A CHEMOTHERAPY AGENT SUCH AS PACLITAXEL, DOCETAXEL, VINCRISTINE, VINBLASTIN, VINORELBIN, VINFLUNIN; IT ALSO REFERS TO THE CRYSTALLINE FORMS I AND II OF N- (2,3-DIHYDROXY-PROPOXI) -3,4-DIFLUORO-2- (2-FLUORO-4-IODO-PHENYLAMINE) -BENZAMIDE THAT IS CHARACTERIZED BY ITS PATTERN OF X-RAY DIFFRACTION. THE PREFERRED COMPOUNDS ARE 3,4 DIFLUORO-2- (2-FLUORO-4-IODO-PHENYLAMINE) -N- (2-HYDROXY-ETOXY) -BENZAMIDE, 5- ...
Подробнее